Pernilla Abrahamsson - Lipum AB Chief Officer
| LIPUM Stock | SEK 18.00 2.80 13.46% |
Insider
Pernilla Abrahamsson is Chief Officer of Lipum AB
| Age | 51 |
| Phone | 46 9 03 40 34 30 |
| Web | https://www.lipum.se |
Lipum AB Management Efficiency
The company has return on total asset (ROA) of (0.9118) % which means that it has lost $0.9118 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.8072) %, meaning that it generated substantial loss on money invested by shareholders. Lipum AB's management efficiency ratios could be used to measure how well Lipum AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Dominique Tersago | Cantargia AB | 61 | |
| Despina Hedin | Ascelia Pharma AB | 37 | |
| Sofie Jansson | NextCell Pharma AB | 37 | |
| Ulrika Harndahl | Annexin Pharmaceuticals AB | N/A | |
| Magnus Corfitzen | Ascelia Pharma AB | 48 | |
| Susan Suchdev | Annexin Pharmaceuticals AB | 51 | |
| Carl MD | Ascelia Pharma AB | 60 | |
| MSc LLM | Annexin Pharmaceuticals AB | N/A | |
| Anna MD | Annexin Pharmaceuticals AB | 50 | |
| Henrik Palm | Annexin Pharmaceuticals AB | 65 | |
| Edvard Smith | NextCell Pharma AB | 72 | |
| Marta MD | AlzeCure Pharma | 67 | |
| Kjell Sjstrm | Cantargia AB | N/A | |
| Ignacio GarciaRibas | Cantargia AB | N/A | |
| Adnan Deronic | Cantargia AB | N/A | |
| Johanna Christensen | Cantargia AB | N/A | |
| Susanne Lagerlund | Cantargia AB | N/A | |
| Lindsay Davies | NextCell Pharma AB | 44 | |
| Anders MSc | NextCell Pharma AB | 82 | |
| Julie Brogren | Ascelia Pharma AB | 51 | |
| Peter Madsen | Cantargia AB | N/A | |
Management Performance
| Return On Equity | -1.81 | |||
| Return On Asset | -0.91 |
Lipum AB Leadership Team
Elected by the shareholders, the Lipum AB's board of directors comprises two types of representatives: Lipum AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lipum. The board's role is to monitor Lipum AB's management team and ensure that shareholders' interests are well served. Lipum AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lipum AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pernilla Abrahamsson, Chief Officer | ||
| Associate Lindquist, CoFounder Research | ||
| Pr Hernell, CoFounder Director | ||
| Marina Norberg, Chief Officer | ||
| Einar Ponten, Chief Officer |
Lipum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lipum AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.81 | |||
| Return On Asset | -0.91 | |||
| Operating Margin | 117.68 % | |||
| Current Valuation | 98.1 M | |||
| Shares Outstanding | 7.65 M | |||
| Shares Owned By Insiders | 81.67 % | |||
| Shares Owned By Institutions | 8.14 % | |||
| Price To Book | 35.65 X | |||
| Price To Sales | 3,380 X | |||
| Gross Profit | (48.69 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lipum Stock Analysis
When running Lipum AB's price analysis, check to measure Lipum AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipum AB is operating at the current time. Most of Lipum AB's value examination focuses on studying past and present price action to predict the probability of Lipum AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipum AB's price. Additionally, you may evaluate how the addition of Lipum AB to your portfolios can decrease your overall portfolio volatility.